Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 141-147

  Seibert, Johannes ^a   Tracik, Ferenc ^b,c   Articus, Konstantin ^b   Spittler, Stefan ^d  

^a Outpatient Clinic   (Germany)

^b Novartis Pharma   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Krankenhaus Maria Hilf   (Germany)

Author keywords

Alzheimer's disease; Rivastigmine patch; Treatment practice

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; MELPERONE; MIRTAZAPINE; NEUROLEPTIC AGENT; PIPAMPERONE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; VENLAFAXINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; CAREGIVER BURDEN SCALE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLOCK DRAWING TEST; CONTACT DERMATITIS; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INTOXICATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ERYTHEMA; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HALLUCINATION; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DEFICIENCY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RESTLESSNESS; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISORDER; SUICIDE; THORAX DISEASE; TRANSDERMAL PATCH; TREATMENT DURATION; URINARY TRACT DISEASE; VALIDITY; VOMITING;

EID: 84859550539     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S29116     Document Type: Article

References (10)

1. Bickel H. Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. Gesundheitswesen. 2000; 62(4):211-218.
2. Ziegler U, Doblhammer G. Prevalence and incidence of dementia in Germany - a study based on data from the public sick funds in 2002. Gesundheitswesen. 2009;71(5):281-290.
3. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10): 1236-1248.
4. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, doubleblind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurol. 2007;69(4 Suppl 1):S14-S22.
5. Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2009;2: 245-254.
6. Winblad B, Cummings J, Andreasen N, et al. A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-467.
7. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(5):485-491.
8. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl. 2002;(127):64-72.
9. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8): 707-714.
10. Verny M, Fremont P, Bourrin JC, Bourdeix I, Pere JJ. Reduced psychotropic drug use in patients with Alzheimer's disease receiving rivastigmine: results of the EXELAN study. J Drug Assess. 2004;7: 123-132.